NVAX
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Novavax, Inc. (NVAX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A-); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | D- (0.8) | D (1.4) | A- (4.1) | C+ (2.6) | C (2.4) |
| 2026-11-06 | B- (3.0) | D+ (1.8) | D (1.3) | A- (4.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-30 | B- (3.0) | D+ (1.8) | D (1.4) | A- (4.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-23 | B- (3.0) | D+ (1.8) | D (1.4) | B+ (3.8) | C+ (2.6) | C+ (2.5) |
| 2026-10-16 | B- (3.0) | D+ (1.8) | D (1.4) | B (3.4) | C+ (2.6) | C (2.4) |